Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business for $1.55 Billion Upfront, Gaining First-in-Class Oral Myosin Inhibitor Sevasemten

PharmRong DataMonitoring shows: June 1, 2026, a foundation-managed pharmaceutical group from FranceServierAnnounced the signing of an agreement to acquireEdgewise Therapeutics Inc.(Nasdaq: EWTX) muscular dystrophy business.

The total transaction amount may reach up to$2.65 billion, including$1.55 billion upfront paymentand the highest$1.1 Billion in Regulatory and Commercial Milestone Payments. The transaction has been approved by the governance bodies of both parties, subject to regulatory approval and the satisfaction of customary closing conditions, and is expected toQ3 2026Completed.

Yao Rong Quan previously published an in-depth research article last September,2017: A Dark Horse Biotech Emerges, Striking Gold in the Blue Ocean of Muscle Disease Therapies. The market capitalization tripled.

This acquisition covers the relevant technical capabilities of Edgewise Therapeutics' muscular dystrophy business, andsevasemten—— An investigational, oral,First-in-class Fast Skeletal Muscle Myosin Inhibitor, its mechanism of action is to protect unstable muscles in patients with rare muscular dystrophy, avoiding contraction-induced injury.

Currently, sevasemten is undergoingKey Cohort Study of Becker Muscular Dystrophy (BMD), andPhase 2 Clinical Trial of Duchenne Muscular Dystrophy (DMD)This candidate drug is poised to establish Servier as a global pharmaceutical company with robust R&D capabilities and a strong pipeline in the field of neuromuscular diseases, while advancing its “Servier 2030” strategic vision for neuroscience.

Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) are both rare, progressive, X-linked genetic disorders caused by the absence or inactivation of functional dystrophin, leading to irreversible muscle weakness and atrophy. BMD follows a slower disease progression,No approved therapies are currently available; DMD is more severe, and patients typically lose the ability to walk in early adolescence.Median life expectancy is approximately 30 years.。

References: